The pharmaceutical and medical sector broke out collectively,BeiGene(06160.HK) rose more than 16%,Cinda Bio(01801.HK)Minimally Invasive Medicine(00853.HK) 、Zhaoyan New Drug(06127.HK) both rose more than 9%,JD Health(06618.HK)Hygeia Medical(01385.HK) both rose more than 7%.
On September 23-25, the 5th “China Health Industry Capital Summit” hosted by Zhongkang Technology will be held at the Golden Coast of the Boao Forum for Asia in Hainan.big hotelGrand opening.
BeiGene(06160.HK): On September 13, the new drug of its anti-PD-1 antibody drug Bezan (tislelizumab injection) was accepted by the FDA for the treatment of esophageal squamous cell carcinoma; on the 15th, the US FDA granted 100 Yueze (Zebutinib) has accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma.
Cinda Bio(01801.HK): On September 15, according to the latest announcement from the Center for Drug Evaluation (CDE) of the State Drug Administration of China,Cinda BioThe development of two bispecific antibodies, IBI389 targeting CD3/Claudin 18.2 and IBI322 targeting CD47/PD-L1, have been clinically applied for the default license.
Hygeia Medical(01385.HK): On September 14, 2021, Qihai Pharmaceutical, a wholly-owned subsidiary of the company, entered into drug procurement agreements with Handan Renhe Hospital and Kaiyuan Jiehua Hospital; and Jiangsu Supply Chain, a wholly-owned subsidiary of the company Signed purchase agreements for medical consumables with Handan Renhe Hospital and Kaiyuan Jiehua Hospital.
According to Frost & Sullivan data, the global anti-tumor drug market will reach US$150.3 billion in 2020. It is estimated that by 2025, its market size will reach US$304.8 billion, with a compound annual growth rate of 15.2% from 2020 to 2025.
(Source: Caihua News Agency)